{"id":"NCT00866658","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2009-03-20","resultsPosted":"2016-10-11","lastUpdate":"2016-10-11"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClikÂ®"]},{"type":"DRUG","name":"Sulfonylurea","otherNames":[]},{"type":"DRUG","name":"Basal Insulin","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.\n\nThe primary objective is to assess the effects of lixisenatide, when added to basal insulin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on body weight, 2-hour postprandial plasma glucose (PPG) after standardized meal challenge test, percentage of patients reaching HbA1c less than 7 percent (%), percentage of patients reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), change in 7-point self-monitored plasma glucose (SMPG) profiles, change in daily basal insulin and total insulin doses; to evaluate safety, tolerability, pharmacokinetics (PK), and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.11,"sd":0.131},{"arm":"Lixisenatide","deltaMin":-0.77,"sd":0.137}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":29},"locations":{"siteCount":4,"countries":["Japan","Philippines","South Korea","Taiwan"]},"refs":{"pmids":["22564709","31956422","26039935"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":157},"commonTop":["Hypoglycaemia","Nausea","Nasopharyngitis","Vomiting","Asthenia"]}}